SCHEMBL2179808

SCHEMBL2179808

COC(=O)C(C(C)C)N1Cc2ccc(-c3ccc(NC(=O)c4cccnc4Cl)cc3)cc2C1=O

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.44
TP53 P04637 1/20 0.44
MAPT P10636 5/20 0.43
ALDH1A1 P00352 4/20 0.43
RAB9A P51151 3/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
KDM4E B2RXH2 2/20 0.42
GAA P10253 2/20 0.42
HTT P42858 2/20 0.41
NPC1 O15118 1/20 0.41
ATM Q13315 1/20 0.41
GRM4 Q14833 1/20 0.40
POLB P06746 1/20 0.39
NR2E3 Q9Y5X4 1/20 0.39
TDP1 Q9NUW8 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13719199 1.00 LMNA (0.44) LMNATP53MAPTALDH1A1RAB9A
SCHEMBL13719068 0.92 ALDH1A1 (0.44) LMNATP53MAPTALDH1A1RAB9A
SCHEMBL2178639 0.92 ALDH1A1 (0.44) LMNATP53MAPTALDH1A1RAB9A
SCHEMBL2180791 0.88 LMNA (0.48) LMNATP53MAPTRAB9AKMT2A
SCHEMBL13719200 0.85 GAA (0.42) LMNAMAPTALDH1A1RAB9AMEN1
SCHEMBL2177686 0.85 TP53 (0.44) LMNATP53MAPTRAB9AKMT2A
SCHEMBL2181618 0.84 LMNA (0.51) LMNATP53MAPTALDH1A1RAB9A
SCHEMBL2181234 0.84 LMNA (0.47) LMNATP53MAPTRAB9AKMT2A
SCHEMBL2181507 0.83 MEN1 (0.46) LMNATP53MAPTALDH1A1RAB9A
SCHEMBL2180669 0.83 LMNA (0.47) LMNATP53RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT LMNA 2193/4885TP53 2093/4885MAPT 116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.